Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd
ASX:PTX
Price:
0.048 AUD
-4%
Market Closed
Updated:
May 3, 2024
Prescient Therapeutics Ltd
Cash from Operating Activities
|
Prescient Therapeutics Ltd
Cash from Operating Activities Peer Comparison
Comparables:
IMM
MSB
CSL
CUV
TLX
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Cash from Operating Activities
-AU$1.5m
|
CAGR 3-Years
25%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-6%
|
|
|
Immutep Ltd
ASX:IMM
|
Cash from Operating Activities
-AU$35.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-10%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$2.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Operating Activities
AU$42.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
AU$23.9m
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Prescient Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-1.5m
AUD
-1.5m
AUD
Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Cash from Operating Activities amounts to -1.5m AUD.
What is Prescient Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-6%
-6%
Over the last year, the Cash from Operating Activities growth was 69%. The average annual Cash from Operating Activities growth rates for Prescient Therapeutics Ltd have been 25% over the past three years , 11% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
